Consumer healthcare group Haleon on Thursday announced that it has entered into a binding agreement for the sale of the ChapStick brand to Suave Brands
Company, a company owned by American private equity firm Yellow Wood Partners.
The British consumer healthcare company has agreed to sell its lip balm brand to Suave for about $430 million in cash and a minority interest in the buyer,
valued at around $80 million.
Haleon, which was spun off from the GSK Group in July 2022, said that cash proceeds from the sale would be used to pay down debt.
ChapStick generated £112 million ($142.5 million) in revenue in 2023, said Haleon, adding that the sale is likely to close in the second quarter of 2024.
Brian McNamara, Chief Executive Officer, Haleon, said: "Today's announcement is consistent with Haleon being proactive in managing our portfolio, and being
rigorous and disciplined where there are opportunities for divestment.
"While ChapStick is a great brand, much loved by consumers around the world, it is not a core focus for Haleon.
In a long scripted overhaul of its business, GlaxoSmithKline spun off its consumer health business on Monday (July 18) in the biggest listing in Europe for
more than a decade.
The new company, Haleon, becomes the world's biggest standalone consumer health business, home to brands including Sensodyne toothpaste, pain relief drug Panadol
and cold treatment Theraflu.
Shares in Haleon started trading at 330 pence on Monday morning, giving the business a market valuation of around £30.5 billion - dashing high hopes for Haleon's
much higher market valuation after GSK in January said it had rebuffed a £50 billion offer from Unilever on the basis it was too low.
The major strategy shift by GSK chief executive Emma Walmsley to focus on the company's core pharmaceuticals business comes after she faced intense activist
shareholder pressure over its delays in producing Covid jabs and treatments.
Shares in GSK, Sanofi and Haleon fell sharply on Thursday (August 11) amid growing investor concerns about US litigation focused on a heartburn drug that
contained a probable carcinogen, while Johnson and Johnson has decided to end sales of talcum powder after cancer claims.
GSK shares were down 6.8 per cent, Sanofi's were down 6.9 per cent and Haleon's down per cent.
GSK and Sanofi at various points sold the drug - originally branded as Zantac - which US regulators ordered off the market in 2020. Haleon, spun out as an independent
listed company last month, comprises consumer health assets once partly owned by GSK.
The prospect of impending litigation is not new. Among other disclosures, recently-listed Haleon had highlighted the risk of such lawsuits in its prospectus.
The topic has arrived in investor consciousness in recent days it seems, but has been rumbling on in the background for a few years, Deutsche Bank analysts wrote in a
note.
US drugs giant Pfizer will exit its consumer healthcare joint venture with GlaxoSmithKline after the unit is spun off next month, the British drugmaker
said Wednesday (June 1).
GSK will list the healthcare division on the London stock market on July 18 as it looks to concentrate on the pharmaceutical business, it said in a statement.
The London-listed firm currently owns a majority 68 percent of the unit, with Pfizer holding the remainder.
"Pfizer intends to exit its 32-percent ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders," GSK
said.
Covid jab maker Pfizer is seeking to pursue its focus on "innovative medicines and vaccines", it noted.
The unit, which will be named Haleon after the demerger, makes products including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.